Glyburide/glipizide combination therapy in type 2 diabetes

摘要: Objective: Research has determined differences in the pharmacokinetics and therapeutic actions of glyburide glipizide. The goal this study was to evaluate hypoglycemic effects glyburide/glipizide combinationtherapy management patients with diabetes not adequately controlled on either agent alone. Methods: Nine (3 men, mean age 50.6 ′ 11 y) who were hyperglycemic or glipizide monotherapy continued their previous regimen doses titrated up maximum daily dietary therapy for 4 weeks, then they placed morning glipizide/evening combination 12 weeks. Results: Combination had no significant effect glycemic control; glycosylated hemoglobin (Hb A I C ) observed (baseline, 15.3% 3.6%; monotherapy, 14.8% 3.3%; combination, 13.4% 3.5%). However, during combined therapy, fasting plasma glucose significantly reduced by 53.4 20.0 mg/dL young (age <50 increased 73.7 26.9 older subjects. Hb 3.8% 4.0% 1.7% 1.3% No changes blood pressure, body weight, lipid parameters occurred. Conclusions: Our preliminary data indicate limited usefulness therapy. modest reduction hyperglycemia younger than 50 years warrant future studying.